This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Early neurologic deterioration (END) is a frequent complication of acute ischemic stroke and is often due to progressive tissue infarction. In their single-center analysis of acute lacunar stroke identified on magnetic resonance imaging (n = 365), Dr. Vynckier and colleagues report 16.7% of patients experienced a worsening of 2 or more points in the NIH Stroke Scale within 24 hours of arrival and were classified as having END. It is important that milder stroke severity, ventral pontine injury, capsular warning syndrome, and hypoperfusion on baseline imaging were predictive of END. Dr. Alpert comments that early mobilization—while important for expediting rehabilitation and discharge—may increase the risk of END. Dr. Zini and colleagues also highlight the putative relationship between END and branch atheromatous disease, which may be targeted with combination antiplatelet therapy. Indeed, the study by Vynckier et al. found that acute dual antiplatelet therapy was associated with a 90% lower chance of END (adjusted odds ratio 0.10, 95% CI 0.01–0.89). Dual antiplatelet therapy may be useful for preventing progressive tissue infarction in lacunar disease; however, this can only be confirmed in a randomized clinical trial.
Early neurologic deterioration (END) is a frequent complication of acute ischemic stroke and is often due to progressive tissue infarction. In their single-center analysis of acute lacunar stroke identified on magnetic resonance imaging (n = 365), Dr. Vynckier and colleagues report 16.7% of patients experienced a worsening of 2 or more points in the NIH Stroke Scale within 24 hours of arrival and were classified as having END. It is important that milder stroke severity, ventral pontine injury, capsular warning syndrome, and hypoperfusion on baseline imaging were predictive of END. Dr. Alpert comments that early mobilization—while important for expediting rehabilitation and discharge—may increase the risk of END. Dr. Zini and colleagues also highlight the putative relationship between END and branch atheromatous disease, which may be targeted with combination antiplatelet therapy. Indeed, the study by Vynckier et al. found that acute dual antiplatelet therapy was associated with a 90% lower chance of END (adjusted odds ratio 0.10, 95% CI 0.01–0.89). Dual antiplatelet therapy may be useful for preventing progressive tissue infarction in lacunar disease; however, this can only be confirmed in a randomized clinical trial.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
